T. Rowe Price Associates’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$406M Buy
11,060,680
+1,372,418
+14% +$65M 0.05% 287
2025
Q4
$493M Buy
9,688,262
+4,836,285
+100% +$247M 0.05% 270
2025
Q3
$269M Sell
4,851,977
-1,351,287
-22% -$79.1M 0.03% 391
2025
Q2
$428M Buy
6,203,264
+878,598
+17% +$59.8M 0.05% 295
2025
Q1
$370M Sell
5,324,666
-1,020,452
-16% -$84.3M 0.05% 314
2024
Q4
$546M Sell
6,345,118
-3,238,317
-34% -$350M 0.06% 254
2024
Q3
$1.14B Buy
9,583,435
+79,671
+0.8% +$10.6M 0.13% 150
2024
Q2
$1.36B Buy
9,503,764
+914,542
+11% +$121M 0.16% 124
2024
Q1
$1.1B Buy
8,589,222
+823,036
+11% +$98M 0.14% 157
2023
Q4
$803M Sell
7,766,186
-464,729
-6% -$46M 0.11% 183
2023
Q3
$749M Buy
8,230,915
+576,025
+8% +$50.7M 0.11% 188
2023
Q2
$619M Buy
7,654,890
+83,770
+1% +$6.84M 0.09% 221
2023
Q1
$602M Buy
7,571,120
+7,102,208
+1,515% +$504M 0.09% 222
2022
Q4
$31.7M Buy
+468,912
New +$27.5M 0.01% 793
2020
Q2
Sell
-713,596
Closed -$21.5M 2529
2020
Q1
$21.5M Buy
+713,596
New +$21.2M ﹤0.01% 1048

Other funds holding NVO